Preliminary experiments on effects of monoamine oxidase inhibitors on medium levels (pmol/well, means ± S.E.M.) of catechols after 180 minutes
Numbers of replicates are in parentheses.
| Drug | DOPAL | DOPAC | DOPET | DOPA | DA |
|---|---|---|---|---|---|
| Control (3) | 137 ± 2 | 743 ± 37 | 726 ± 15 | 24.9 ± 1.0 | 147 ± 7 |
| Minaprine, 30 µM (2) | 366 ± 25 | 628 ± 115 | 801 ± 8 | 23.1 ± 1.9 | 171 ± 6 |
| Moclobemide, 30 µM (3) | 130 ± 4 | 591 ± 22 | 782 ± 7 | 21.3 ± 0.4 | 225 ± 5 |
| Toloxatone, 30 µM (3) | 58 ± 1 | 253 ± 19 | 358 ± 7 | 15.7 ± 0.4 | 372 ± 14 |
| Pargyline, 10 µM (3) | 27 ± 3 | 176 ± 6 | 286 ± 5 | 14.5 ± 0.3 | 234 ± 9 |
| Clorgyline, 10 µM (3) | 6.6 ± 0.0 | 128 ± 9 | 188 ± 1 | 9.6 ± 0.5 | 462 ± 5 |
| Control (4) | 173 ± 1 | 510 ± 16 | 311 ± 10 | 8.9 ± 0.2 | 79 ± 13 |
| Toloxatone, 3 µM (4) | 69 ± 1 | 228 ± 5 | 127 ± 5 | 5.5 ± 0.2 | 121 ± 6 |
| Toloxatone, 10 µM (4) | 47 ± 1 | 155 ± 4 | 87 ± 1 | 5.1 ± 0.1 | 135 ± 6 |
| Toloxatone, 30 µM (4) | 27 ± 0 | 77 ± 2 | 56 ± 2 | 4.4 ± 0.1 | 141 ± 7 |
| Toloxatone, 100 µM (4) | 19 ± 0 | 47 ± 2 | 48 ± 2 | 4.1 ± 0.1 | 135 ± 3 |
| Pargyline, 10 µM (2) | 16 ± 1 | 52 ± 0 | 57 ± 2 | 3.8 ± 0.0 | 101 ± 2 |
| Clorgyline, 10 µM (2) | 1 ± 0 | 1 ± 0 | 0 ± 0 | 11.3 ± 1.4 | 1282 ± 26 |
| Control (4) | 83 ± 2 | 463 ± 15 | 307 ± 8 | 7.8 ± 0.4 | 213 ± 8 |
| Pargyline, 100 nM (4) | 21 ± 1 | 179 ± 10 | 141 ± 5 | 8.7 ± 0.3 | 217 ± 18 |
| Pargyline, 1 µM (4) | 20 ± 1 | 122 ± 2 | 139 ± 3 | 8.2 ± 0.1 | 210 ± 11 |
| Pargyline, 10 µM (4) | 14 ± 1 | 89 ± 5 | 92 ± 3 | 6.9 ± 0.1 | 242 ± 16 |
| Rasagiline, 100 nM (4) | 29 ± 1 | 120 ± 1 | 136 ± 2 | 7.4 ± 0.3 | 194 ± 8 |
| Rasagiline, 1 µM (4) | 24 ± 1 | 90 ± 3 | 104 ± 1 | 6.8 ± 0.2 | 178 ± 7 |
| Rasagiline, 10 µM (4) | 19 ± 1 | 71 ± 2 | 77 ± 3 | 6.1 ± 0.3 | 188 ± 4 |
| Clorgyline, 100 nM (4) | 9 ± 1 | 59 ± 1 | 41 ± 1 | 6.6 ± 0.1 | 249 ± 8 |
| Clorgyline, 1 µM (4) | 7 ± 0 | 62 ± 1 | 41 ± 0 | 6.5 ± 0.2 | 250 ± 13 |
| Clorgyline, 10 µM (4) | 8 ± 0 | 61 ± 2 | 47 ± 1 | 3.5 ± 0.1 | 308 ± 15 |